Trade

with

Hemispherx Biopharma Inc
(Amex: HEB)
AdChoices
0.3006
-0.0144
-4.57%
After Hours :
0.3000
-0.0006
-0.20%

Open

0.3210

Previous Close

0.3150

Volume (Avg)

2.97M (1.65M)

Day's Range

0.2934-0.3240

52Wk Range

0.1900-0.5500

Market Cap.

59.85M

Dividend Rate ( Yield )

-

Beta

1.05

Shares Outstanding

195.38M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 150.00k

    • Net Income

    • -16.23M

    • Market Cap.

    • 59.85M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -9,305.98

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.05

    • Forward P/E

    • -3.15

    • Price/Sales

    • 303.03

    • Price/Book Value

    • 2.04

    • Price/Cash flow

    • -4.10

      • EBITDA

      • -15.34M

      • Return on Capital %

      • -42.97

      • Return on Equity %

      • -52.27

      • Return on Assets %

      • -42.97

      • Book Value/Share

      • 0.15

      • Shares Outstanding

      • 195.38M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 3.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.10

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -10.76

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -457.07

            • 82.75

            • Pre-Tax Margin

            • -9,305.98

            • 39.38

            • Net Profit Margin

            • -9,305.98

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -684.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -9,280.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.00

              • 0.76

              • Current Ratio

              • 4.92

              • 2.92

              • Quick Ratio

              • 4.86

              • 2.35

              • Interest Coverage

              • -1,425.92

              • 38.02

              • Leverage Ratio

              • 1.14

              • 2.21

              • Book Value/Share

              • 0.15

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.21

                • 277.78

                • P/E Ratio 5-Year High

                • -18.64

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.76

                • 124.82

                • Price/Sales Ratio

                • 303.03

                • 9.35

                • Price/Book Value

                • 2.04

                • 8.50

                • Price/Cash Flow Ratio

                • -4.10

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -52.27

                    (-33.60)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -42.97

                    (-29.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -47.01

                    (-33.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.00

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -17.17M
                  Operating Margin
                  -11,444.67
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -4.10
                  Ownership

                  Institutional Ownership

                  5.94%

                  Top 10 Institutions

                  5.87%

                  Mutual Fund Ownership

                  3.12%

                  Float

                  98.37%

                  5% / Insider Ownership

                  1.35%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,796,855

                  • 0.00

                  • 1.47

                  • Vanguard Extended Market Index Fund

                  •  

                    1,888,269

                  • 3.08

                  • 0.99

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    646,292

                  • 0.00

                  • 0.34

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    130,774

                  • 0.00

                  • 0.07

                  • Vanguard Balanced Index Fund

                  •  

                    110,190

                  • 0.00

                  • 0.06

                  • Vanguard Instl Total Stock Market Index

                  •  

                    96,879

                  • 0.00

                  • 0.05

                  • DFA U.S. Micro Cap Portfolio

                  •  

                    93,100

                  • 0.00

                  • 0.05

                  • The Vanguard - Total Stk Mkt Idx Trust. CF

                  •  

                    92,360

                  • 0.00

                  • 0.05

                  • Vanguard US Equity Index

                  •  

                    32,400

                  • 0.00

                  • 0.02

                  • Wilshire Micro-Cap ETF

                  •  

                    29,086

                  • 0.00

                  • 0.02

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    4,769,253

                  • +5.72%

                  • 2.52

                  • BlackRock Fund Advisors

                  •  

                    4,509,897

                  • +13.14%

                  • 2.38

                  • Geode Capital Management, LLC

                  •  

                    777,066

                  • 0.00%

                  • 0.41

                  • Dimensional Fund Advisors, Inc.

                  •  

                    278,900

                  • -3.19%

                  • 0.15

                  • Northern Trust Investments, N.A.

                  •  

                    237,271

                  • -2.19%

                  • 0.13

                  • BB&T SECURITIES, LLC

                  •  

                    170,000

                  • +900.00%

                  • 0.09

                  • Wedbush Morgan Securities Inc.

                  •  

                    111,500

                  • -23.89%

                  • 0.06

                  • State Street Corp

                  •  

                    89,200

                  • 0.00%

                  • 0.05

                  • Guggenheim Capital LLC

                  •  

                    80,521

                  • -9.09%

                  • 0.04

                  • BNY Mellon Asset Management Ltd.

                  •  

                    68,983

                  • +3.46%

                  • 0.04

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Value

                  Hemispherx Biopharma, Inc. is a Delaware Corporation founded in the early 1970s. The Company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhanc...moreing technologies for the treatment of viral and immune based chronic disorders. Since its inception, it has established a foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. The Company owns and operates a 43,000 sq. ft. manufacturing facility in New Brunswick, NJ that produces Alferon and Ampligen. The Company operates in one segment...more, which performs research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company’s primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). As of December 31, 2013, the Company had 25 patents. Its potential competitors are among the largest pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities. The Company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work.lessless

                  Key People

                  William A. Carter,M.D.

                  CEO/Chairman of the Board/Chief Scientific Officer/Director/President

                  Thomas K. Equels

                  CFO/Director/General Counsel/Secretary/Vice Chairman of the Board

                  Dr. Ralph Christopher Cavalli, PhD

                  Vice President, Divisional

                  Dr. Iraj-Eqhbal Kiani,PhD

                  Director

                  Dr. William M. Mitchell, M.D.

                  Director

                  • Hemispherx Biopharma Inc

                  • 1617 JFK Boulevard

                  • Philadelphia, PA 19103

                  • USA.Map

                  • Phone: +1 215 988-0080

                  • Fax: +1 215 988-1739

                  • hemispherx.net

                  Incorporated

                  1970

                  Employees

                  39

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: